Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory announced today the launch of a national awareness campaign – Know Your Count – aimed at raising awareness of the seriousness of asthma and educating asthma patients and caregivers about the importance of keeping track of the remaining doses in their rescue inhalers. The campaign features award-winning singer and actress, Kristin Chenoweth, who is speaking publicly for the first time about the impact her asthma has had on her professional career and busy lifestyle. For more information about the Know Your Count campaign, Kristin’s experience with asthma and to view an important public service announcement (PSA), visit www.KnowYourCount.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65058-teva-respiratory-aafa-know-your-count-managing-asthma/
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.
Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
CVS Caremark (NYSE: CVS) announced today that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the U.S. by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of its patients and customers.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65510-cvs-caremark-to-stop-selling-tobacco-products-at-cvs-pharmacy-locations
The following statement is being issued by Jonathan Schochor, Chairman, Plaintiffs’ Steering Committee, regarding Jane Doe No. 1, et. al. v. Johns Hopkins Hospital, et al., No. 24-C-13-001041.
If you were a patient of, or treated by Johns Hopkins Hospital gynecologist, Dr. Nikita Levy, you are a member of a mandatory settlement class action.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65136-dr-nikita-levy-class-action-lawsuit-johns-hopkins-hospital-gynecology
With the introduction of Abbott's iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in one three-second scan to determine the patient's visual abnormalities. This highly advanced diagnostic tool measures the internal optics and surface of the eye more precisely than conventional methods, allowing doctors to fully evaluate imperfections that result in poor vision. Obtaining these measurements in one three-second scan enables ophthalmologists to screen patients more efficiently to determine if they are eligible for LASIK or other refractive surgery and to assist in diagnosis of other conditions.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64467-abbott-idesign-dx-system-available-for-opthalmologists-and-patients
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
